Artem A. Derkaev

Moscow, MOW 123098, Russian Federation

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

Structural basis of influenza A virus neutralization by broadly reactive single-domain antibody G2.3 recognizing glycosylated epitope within hemagglutinin stem domain.

Structural basis of influenza A virus neutralization by broadly reactive single-domain antibody G2.3 recognizing glycosylated epitope within hemagglutinin stem domain.

Journal: International journal of biological macromolecules
Published: April 06, 2026

Long-term protective potency of AAV vector-based SARS-CoV-2 prophylaxis in mice and non-human primates.

Long-term protective potency of AAV vector-based SARS-CoV-2 prophylaxis in mice and non-human primates.

Journal: Frontiers in immunology
Published: March 12, 2026

Broadly neutralizing single-domain antibody targeting the spike NTD displays therapeutic efficacy against diverse SARS-CoV-2 variants.

Broadly neutralizing single-domain antibody targeting the spike NTD displays therapeutic efficacy against diverse SARS-CoV-2 variants.

Journal: Frontiers in immunology
Published: January 29, 2026

Circular mRNA against CleanCap linear mRNA vectors: comprehensive comparison, expression, active and passive immunization.

Circular mRNA against CleanCap linear mRNA vectors: comprehensive comparison, expression, active and passive immunization.

Journal: Frontiers in immunology
Published: October 29, 2025

Ultra-potent RBM-specific single-domain antibody broadly neutralizes multiple SARS-CoV-2 variants with picomolar activity.

Ultra-potent RBM-specific single-domain antibody broadly neutralizes multiple SARS-CoV-2 variants with picomolar activity.

Journal: International journal of biological macromolecules
Published: February 18, 2025

Structural Basis for Evasion of New SARS-CoV-2 Variants from the Potent Virus-Neutralizing Nanobody Targeting the S-Protein Receptor-Binding Domain.

Structural Basis for Evasion of New SARS-CoV-2 Variants from the Potent Virus-Neutralizing Nanobody Targeting the S-Protein Receptor-Binding Domain.

Journal: Biochemistry. Biokhimiia
Published: September 01, 2024

Broadly Reactive Nanobody Targeting the H3 Hemagglutinin of the Influenza A Virus.

Broadly Reactive Nanobody Targeting the H3 Hemagglutinin of the Influenza A Virus.

Journal: Acta naturae
Published: January 24, 2024

rAAV expressing recombinant antibody for emergency prevention and long-term prophylaxis of COVID-19.

rAAV expressing recombinant antibody for emergency prevention and long-term prophylaxis of COVID-19.

Journal: Frontiers in immunology
Published: December 21, 2022

Single-domain antibody delivery using an mRNA platform protects against lethal doses of botulinum neurotoxin A.

Single-domain antibody delivery using an mRNA platform protects against lethal doses of botulinum neurotoxin A.

Journal: Frontiers in immunology
Published: November 14, 2022

rAAV expressing recombinant neutralizing antibody for the botulinum neurotoxin type A prophylaxis.

rAAV expressing recombinant neutralizing antibody for the botulinum neurotoxin type A prophylaxis.

Journal: Frontiers in microbiology
Published: June 03, 2022

Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern.

Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern.

Journal: Frontiers in immunology
Published: November 25, 2021

Development of Neutralizing Nanobodies to the Hemagglutinin Stem Domain of Influenza A Viruses.

Development of Neutralizing Nanobodies to the Hemagglutinin Stem Domain of Influenza A Viruses.

Journal: Acta naturae
Published: June 18, 2021
Showing 1-12 of 13

Last Updated: 09/26/2026